LIPO · Lipella Pharmaceuticals Inc.
$0.03
+0.00 (+0.00%)
At close · Jul 29
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 14, 2025
Market Cap
$152,487
Shares
4.62M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$536.36K
+19.3%
FY2024
Net Income
-$5.02M
-8.6%
FY2024
Operating Margin
-947.23%
+108.3pp
FY2024
Diluted EPS
-$4.79
+22.2%
FY2024
Operating Cash Flow
-$3.95M
-25.4%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| $605.9K | $536.36K | $449.62K | $184.16K | $259.35K | |
| $3.57M | $3.61M | $3.04M | $2.55M | $1.46M | |
| $2.23M | $2M | $2.16M | $226.19K | $718.38K | |
| — | $2886 | $1685 | — | — | |
| -$5.41M | -$5.08M | -$4.75M | -$2.59M | -$1.92M | |
| — | -947.23% | -1055.55% | -1406.26% | -738.71% | |
| — | -$5.08M | -$4.74M | — | — | |
| — | — | $10.85K | $9612 | $6834 | |
| $80.2K | $64.28K | $137.84K | $1678 | $104 | |
| $80.2K | $64.28K | $126.99K | -$7979 | $50.36K | |
| -$5.33M | -$5.02M | -$4.62M | -$2.6M | -$1.87M | |
| -$5.33M | -$5.02M | -$4.62M | -$2.6M | -$1.87M | |
| — | -935.25% | -1027.31% | -1410.59% | -719.3% | |
| USD/shares | — | -$4.79 | -$6.16 | -$5.12 | -$4.40 |
| USD/shares | — | -$4.79 | -$6.16 | -$5.12 | -$4.40 |
| shares | — | 1.05M | 750.38K | 507.58K | 426.01K |
| shares | — | 1.05M | 750.38K | 507.58K | 426.01K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Grant Revenues | $536,357 | $449,617 | $184,156 | $259,347 |